Equities research analysts expect that Heska Corp (NASDAQ:HSKA) will post earnings of $0.56 per share for the current quarter, according to Zacks. Two analysts have issued estimates for Heska’s earnings. The highest EPS estimate is $0.59 and the lowest is $0.53. Heska posted earnings of $0.46 per share during the same quarter last year, which would indicate a positive year over year growth rate of 21.7%. The firm is scheduled to report its next earnings results before the market opens on Wednesday, February 28th.

On average, analysts expect that Heska will report full-year earnings of $2.01 per share for the current fiscal year, with EPS estimates ranging from $1.97 to $2.04. For the next year, analysts expect that the company will report earnings of $2.09 per share, with EPS estimates ranging from $1.91 to $2.25. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Heska.

HSKA has been the topic of a number of recent analyst reports. Sidoti raised shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Monday, February 5th. Aegis reissued a “buy” rating on shares of Heska in a research report on Tuesday, December 19th. Raymond James Financial reissued a “buy” rating on shares of Heska in a research report on Monday, December 4th. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, B. Riley reissued a “hold” rating and issued a $96.50 price objective on shares of Heska in a research report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $110.08.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.70% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC grew its stake in Heska by 34.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after acquiring an additional 153,895 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Heska by 31.7% during the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after purchasing an additional 111,232 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Heska during the fourth quarter valued at approximately $23,831,000. Bank of New York Mellon Corp boosted its stake in shares of Heska by 110.1% during the fourth quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock valued at $16,897,000 after purchasing an additional 110,391 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Heska by 12.7% during the second quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock valued at $19,998,000 after purchasing an additional 22,053 shares in the last quarter. Institutional investors and hedge funds own 80.03% of the company’s stock.

Heska (NASDAQ HSKA) traded down $2.16 during trading on Friday, reaching $58.36. 110,700 shares of the company were exchanged, compared to its average volume of 86,494. Heska has a 12 month low of $56.59 and a 12 month high of $115.00. The stock has a market cap of $420.48, a price-to-earnings ratio of 30.72, a P/E/G ratio of 1.57 and a beta of 0.67.

COPYRIGHT VIOLATION WARNING: “Heska Corp (HSKA) Expected to Announce Earnings of $0.56 Per Share” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/14/heska-corp-hska-expected-to-announce-earnings-of-0-56-per-share.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.